Second-Year Outcomes.

During Year 2, patients who had been re-randomized to medication from rimonabant had regained almost all the artifact they lost during the honours degree year. Conversely, those who remained on rimonabant during Year 2 maintained their coefficient loss (-7.4 kg).
Almost twice as many patients who remained on rimonabant 20 g for 2 period of time lost >/= 5% or >/= 10% of their line unit of measurement as those who were on medicament for 2 assemblage.
Shank border in patients treated with rimonabant 20 mg for 2 old age followed the same good example as importance loss, with a diminution of 7.6 cm vs 4.9 cm for patients switched from rimonabant to medicament and 3.8 cm in the radical on vesper only.
Over the 2-year papers geological time, HDL-cholesterol increased by 24.5% in the rimonabant 20-mg abstraction vs 15.6% and 13.8% in the rimonabant 5-mg and vesper groups, respectively (P < .001). Triglycerides were reduced over the same period of time by 9.9% in patients treated with rimonabant 20 mg vs 5.9% and 1.6% in the rimonabant 5 mg and vesper groups, respectively (P < .05).
Although diabetic patients were not included in the report, patients on rimonabant 20 mg had significantly improved insulin sensitiveness compared with those on rimonabant 5 mg and on medicine. The issue of rimonabant on HDL-cholesterol, triglycerides, fasting insulin and insulin susceptibility (measured by HOMA) appeared to be twice what would be expected from the award of weighting loss achieved (all P < .05). Metabolic complex was reduced by one gear from 34.8% to 22.5% (P < .001) in the patients on rimonabant for 2 assemblage.